Arthritis/rheumatic disorders:
Indications for: COSENTYX
Active psoriatic arthritis (PsA) in patients aged ≥2yrs. Active enthesitis-related arthritis (ERA) in patients aged ≥4yrs. Active ankylosing spondylitis (AS) in adults. Active non-radiographic axial spondyloarthritis (nraxSpA) in adults with objective signs of inflammation.
Adult Dosage:
Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: PsA with coexistent plaque psoriasis: 300mg (given as two 150mg SC injections) at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. Other PsA (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks. Consider 300mg every 4 weeks if PsA continues. Cosentyx may be administered with or without MTX. AS (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks. Consider 300mg every 4 weeks if AS continues. nraxSpA (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks.
Children Dosage:
AS or nraxSpA (<18yrs): not established. PsA (<2yrs or <15kg) or ERA (<4yrs or <15kg): not established. PsA (≥2yrs): ≥15–<50kg: 75mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; ≥50kg: 150mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Cosentyx may be administered with or without MTX. ERA (≥4yrs): ≥15–<50kg: 75mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; ≥50kg: 150mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
COSENTYX Warnings/Precautions:
May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. Complete all immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.
COSENTYX Classification:
Interleukin-17A antagonist.
COSENTYX Interactions:
Concomitant live vaccines: not recommended. Non-live vaccines: may get suboptimal response. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.
Adverse Reactions:
Nasopharyngitis, diarrhea, upper respiratory tract infection; inflammatory bowel disease, hypersensitivity reactions, other serious infections.
Generic Drug Availability:
NO
How Supplied:
Single-dose Sensoready pen (150mg)—1, 2; Single-dose prefilled syringe (150mg)—1, 2; (75mg)—1; Single-dose vial—1
Pricing for COSENTYX
Psoriasis:
Indications for: COSENTYX
Moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.
Adult Dosage:
Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: 300mg (given as two 150mg SC injections) at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. For some patients, 150mg dose may be acceptable.
Children Dosage:
<6yrs: not established. Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). Give by SC inj at Weeks 0, 1, 2, 3, and 4 then every 4 weeks thereafter. ≥6yrs (<50kg): 75mg; (≥50kg): 150mg.
COSENTYX Warnings/Precautions:
May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. Complete all immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.
COSENTYX Classification:
Interleukin-17A antagonist.
COSENTYX Interactions:
Concomitant live vaccines: not recommended. Non-live vaccines: may get suboptimal response. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.
Adverse Reactions:
Nasopharyngitis, diarrhea, upper respiratory tract infection; inflammatory bowel disease, hypersensitivity reactions, other serious infections.
Generic Drug Availability:
NO
How Supplied:
Single-dose Sensoready pen (150mg)—1, 2; Single-dose prefilled syringe (150mg)—1, 2; (75mg)—1; Single-dose vial—1
